Stoke Therapeutics, Inc.
Q2 2020 13F Holders
Symbol
STOK
CUSIP
86150R107
Type
Equity
Class
COM
Num filings
72
Total reported value, excl. options
$825 M
Compare 2020 Q2 to
2025 Q1
2024 Q4
2024 Q3
2024 Q2
2024 Q1
2023 Q4
2023 Q3
2023 Q2
2023 Q1
2022 Q4
2022 Q3
2022 Q2
2022 Q1
2021 Q4
2021 Q3
2021 Q2
2021 Q1
2020 Q4
2020 Q3
2020 Q1
2019 Q4
2019 Q3
2019 Q2
Manager
Report Date
Value ($000)
Shares
Option Type